日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Longitudinal Tumor Size and Survival Modeling for Exposure-Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast Cancer

针对频繁减量药物的暴露-反应分析，采用纵向肿瘤大小和生存模型：阿贝西利在转移性乳腺癌患者中的剂量合理性

期刊:Clinical Pharmacology & Therapeutics
影响因子:5.5
doi:10.1002/cpt.70212
Chigutsa, Emmanuel; Chapman, Sonya C; Turner, P Kellie
肿瘤
肿瘤免疫
乳腺癌
发表日期：2026
文献求助 收藏

Dose Accuracy and Reliability of a Connected Insulin Pen System

联网胰岛素笔系统的剂量准确性和可靠性

期刊:Journal of diabetes science and technology
影响因子:3.7
doi:10.1177/19322968241301760
Backfish, Matthew; Kovalchick, Kimberly; Albert, Robert; Rosilio, Myriam; Chigutsa, Farai; Liao, Birong
免疫/内分泌
发表日期：2026
文献求助 收藏

Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials

在 SURMOUNT-1 至 -4 试验中，替尔泽帕肽在肥胖或超重成人（伴或不伴 2 型糖尿病）中的胃肠道耐受性和体重减轻情况

期刊:Diabetes Obesity & Metabolism
影响因子:5.7
doi:10.1111/dom.16176
Rubino, Domenica M; Pedersen, Sue D; Connery, Lisa; Cao, Dachuang; Chigutsa, Farai; Stefanski, Adam; Fraseur Brumm, Julia; Griffin, Ryan; Gerber, Claire
糖尿病
肥胖
代谢
发表日期：2025
文献求助 收藏

A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure-Response Relationship during Treatment of Obesity with Tirzepatide

一种用于定量测定替泽帕肽治疗肥胖症期间身体成分改善情况并表征暴露-反应关系的药代动力学方法

期刊:Clinical Pharmacology & Therapeutics
影响因子:5.5
doi:10.1002/cpt.3750
Chigutsa, Emmanuel; Her, Lucy; Ma, Xiaosu; Urva, Shweta; Schneck, Karen
肥胖
代谢
发表日期：2025
文献求助 收藏

Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials

SURMOUNT-1 和 SURMOUNT-4 临床试验中，使用替拉帕肽治疗达到体重稳定期所需的时间

期刊:Clinical Obesity
影响因子:2.1
doi:10.1111/cob.12734
Horn, Deborah B; Kahan, Scott; Batterham, Rachel L; Cao, Dachuang; Lee, Clare J; Murphy, Madhumita; Gonsahn-Bollie, Sylvia; Chigutsa, Farai; Stefanski, Adam; Dunn, Julia P
NT-4
发表日期：2025
文献求助 收藏

Population pharmacokinetics and pharmacodynamics of nasal glucagon in patients with type 1 or 2 diabetes

鼻腔胰高血糖素在1型或2型糖尿病患者中的群体药代动力学和药效学

期刊:Cpt-Pharmacometrics & Systems Pharmacology
影响因子:3
doi:10.1002/psp4.13153
James, Douglas E; Shen, Tong; Geiser, Jeanne S; Garhyan, Parag; Chigutsa, Emmanuel
糖尿病
代谢
发表日期：2024
文献求助 收藏

Donanemab exposure and efficacy relationship using modeling in Alzheimer's disease

利用模型分析多纳内单抗暴露量与阿尔茨海默病疗效之间的关系

期刊:Alzheimer's and Dementia: Translational Research and Clinical Interventions
影响因子:6.8
doi:10.1002/trc2.12404
Gueorguieva, Ivelina; Willis, Brian A; Chua, Laiyi; Chow, Kay; Ernest, C Steven 2nd; Wang, Jian; Shcherbinin, Sergey; Sims, John R; Chigutsa, Emmanuel
阿尔茨海默症
发表日期：2023
文献求助 收藏

Dose Rationale of Nasal Glucagon in Japanese Pediatric Patients with Diabetes Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation

利用药代动力学/药效学建模和模拟方法，探讨鼻用胰高血糖素在日本糖尿病患儿中的剂量合理性

期刊:Pediatric Drugs
影响因子:3.3
doi:10.1007/s40272-023-00565-y
Nasu, Risa; James, Douglas E; Chigutsa, Emmanuel; Garhyan, Parag; Nagai, Yukiko
糖尿病
代谢
发表日期：2023
文献求助 收藏

Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes

新型每周一次基础胰岛素Fc在1型糖尿病患者中实现了与德谷胰岛素相似的血糖控制效果，且安全性相当。

期刊:
影响因子:
doi:10.2337/dc22-2395
Kazda, Christof M; Bue-Valleskey, Juliana M; Chien, Jenny; Zhang, Qianyi; Chigutsa, Emmanuel; Landschulz, William; Wullenweber, Paula; Haupt, Axel; Dahl, Dominik
代谢
糖尿病
免疫/内分泌
发表日期：2023
文献求助 收藏

Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program

替泽帕肽治疗肥胖症：SURMOUNT临床开发项目的原理和设计

期刊:
影响因子:
doi:10.1002/oby.23612
le Roux, Carel W; Zhang, Shuyu; Aronne, Louis J; Kushner, Robert F; Chao, Ariana M; Machineni, Sriram; Dunn, Julia; Chigutsa, Farai B; Ahmad, Nadia N; Bunck, Mathijs C
肥胖
代谢
发表日期：2023
文献求助 收藏